BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26174493)

  • 1. Kappa Antagonist JDTic in Phase 1 Clinical Trial.
    Chavkin C; Martinez D
    Neuropsychopharmacology; 2015 Aug; 40(9):2057-8. PubMed ID: 26174493
    [No Abstract]   [Full Text] [Related]  

  • 2. A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.
    Buda JJ; Carroll FI; Kosten TR; Swearingen D; Walters BB
    Neuropsychopharmacology; 2015 Aug; 40(9):2059-65. PubMed ID: 25628006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
    Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
    Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
    Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
    ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.
    Munro TA; Berry LM; Van't Veer A; Béguin C; Carroll FI; Zhao Z; Carlezon WA; Cohen BM
    BMC Pharmacol; 2012 May; 12():5. PubMed ID: 22642416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-[
    Schmitt S; Delamare J; Tirel O; Fillesoye F; Dhilly M; Perrio C
    Nucl Med Biol; 2017 Jan; 44():50-61. PubMed ID: 27821345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
    Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
    Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The κ-opioid receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats.
    Uhari-Väänänen J; Raasmaja A; Bäckström P; Oinio V; Carroll FI; Airavaara M; Kiianmaa K; Piepponen P
    Psychopharmacology (Berl); 2018 May; 235(5):1581-1591. PubMed ID: 29492614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
    Beardsley PM; Howard JL; Shelton KL; Carroll FI
    Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
    Jackson KJ; Carroll FI; Negus SS; Damaj MI
    Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.
    Carroll FI; Harris LS; Aceto MD
    Eur J Pharmacol; 2005 Nov; 524(1-3):89-94. PubMed ID: 16236279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
    Thomas JB; Atkinson RN; Rothman RB; Fix SE; Mascarella SW; Vinson NA; Xu H; Dersch CM; Lu Y; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2001 Aug; 44(17):2687-90. PubMed ID: 11495579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.
    Schmitt S; Colloc'h N; Perrio C
    Eur J Med Chem; 2015 Jan; 90():742-50. PubMed ID: 25513968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging.
    Poisnel G; Oueslati F; Dhilly M; Delamare J; Perrio C; Debruyne D; Barré L
    Nucl Med Biol; 2008 Jul; 35(5):561-9. PubMed ID: 18589300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective κ-opioid receptor antagonist JDTic attenuates the alcohol deprivation effect in rats.
    Uhari-Väänänen J; Eteläinen T; Bäckström P; Oinio V; Carroll FI; Raasmaja A; Kiianmaa K; Piepponen P
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1386-1396. PubMed ID: 31679889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
    Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
    J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.